Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654].

Journal of hepatology·2026
Same author

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).

Alimentary pharmacology & therapeutics·2026
Same author

BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update.

Journal of hepatology·2025
Same author

Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.

Journal of hepatology·2025
Same author

Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association.

The Lancet regional health. Europe·2025
Same author

The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment.

Lancet (London, England)·2025

Related Experiment Video

Updated: May 5, 2026

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 3, 2013

12.3K

Chemoembolization for hepatocellular carcinoma.

Jordi Bruix1, Margarita Sala, Josep M Llovet

  • 1BCLC Group, Liver Unit, IDIBAPS, Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain. bruix@ub.edu

Gastroenterology
|October 28, 2004
PubMed
Summary
This summary is machine-generated.

Chemoembolization offers modest survival benefits for advanced hepatocellular carcinoma (HCC) patients with good liver function. Further research is needed to optimize chemotherapy agents and retreatment schedules for this liver cancer treatment.

More Related Videos

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.5K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.7K

Related Experiment Videos

Last Updated: May 5, 2026

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 3, 2013

12.3K
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.5K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.7K

Area of Science:

  • Hepatobiliary Oncology
  • Interventional Radiology
  • Gastroenterology

Background:

  • Hepatocellular carcinoma (HCC) treatment varies by stage, with early tumors amenable to curative therapies.
  • Advanced HCC necessitates local or systemic treatments, often relying on evidence from limited randomized controlled trials (RCTs) and meta-analyses.
  • Chemoembolization is a primary treatment for advanced HCC, combining intra-arterial chemotherapy with ischemia.

Purpose of the Study:

  • To review the efficacy of current hepatocellular carcinoma (HCC) treatments, focusing on chemoembolization for advanced stages.
  • To identify ideal patient candidates for chemoembolization and assess treatment outcomes.
  • To highlight the need for further research to refine chemoembolization protocols.

Main Methods:

  • Analysis of data from randomized controlled trials (RCTs) and meta-analyses on HCC therapies.
  • Evaluation of chemoembolization efficacy in patients with well-preserved liver function (Child-Pugh class A) and specific tumor characteristics.
  • Review of treatment-related mortality and survival advantages associated with different HCC interventions.

Main Results:

  • Chemoembolization provides modest survival advantages for selected advanced HCC patients, with objective response rates of 30%-50%.
  • Ideal candidates (Child-Pugh A, multinodular, asymptomatic, no vascular invasion) represent <15% of HCC cases.
  • Treatment-related mortality for chemoembolization is <4%; no survival benefit shown for embolization or chemotherapy alone.

Conclusions:

  • Chemoembolization is a mainstay for advanced HCC in well-selected patients, balancing response rates against liver function.
  • Further RCTs are crucial to determine optimal chemotherapeutic agents and retreatment schedules for chemoembolization.
  • Efficacy analyses in future trials should account for prognostic factors like symptoms, liver function, and vascular invasion.